# A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

Source: https://onco.cc/trials/nct03862430/  
OnCo record `nct03862430` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of NanO2TM in glioma & glioblastoma, run by NuvOx LLC, active and no longer recruiting.

## Summary

A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM is a phase 2 interventional study registered as NCT03862430 by NuvOx LLC, with 87 participants enrolled, started 2023-03-31 and due to reach its primary completion in 2027-06-30. Interventions recorded: NanO2TM and Placebo Saline Infusion.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03862430
- Phase: 2
- Setting: A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma multiformE: RESTORE
- Sponsor: NuvOx LLC
- Enrolled: 87

## Sources

- ClinicalTrials.gov NCT03862430: https://clinicaltrials.gov/study/NCT03862430

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct03862430.json